A Phase 1, First-in-Human, Open-Label Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-67856633, an Inhibitor of MALT1, in Participants With NHL and CLL

2024-512734-15-00 Protocol 67856633LYM1001 Human pharmacology (Phase I) - First administration to humans Ended

Start 23 Oct 2019 · End 22 May 2025 · Status Ended · 2 EU/EEA countries · 3 sites · Protocol 67856633LYM1001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 63
Countries 2
Sites 3

Non-Hodgkin lymphoma and chronic lymphocytic leukemia

Key facts

Sponsor
Janssen Cilag International
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
23 Oct 2019 → 22 May 2025
Decision date (initial)
2024-07-26
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-512734-15-00
EudraCT number
2018-003549-40

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Non-Hodgkin lymphoma and chronic lymphocytic leukemia

VersionLevelCodeTermSystem organ class
23.1 LLT 10084346 B-cell non-Hodgkin´s lymphoma 100000004848
21.0 LLT 10008976 Chronic lymphocytic leukemia 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Janssen Cilag International

Sponsor organisation
Janssen Cilag International
Address
Turnhoutseweg 30
City
Beerse
Postcode
2340
Country
Belgium

Scientific contact point

Organisation
Janssen Cilag International
Contact name
CTIS Point of Contact

Public contact point

Organisation
Janssen Cilag International
Contact name
CTIS Point of Contact

Locations

2 EU/EEA countries · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Ended 57 2
Greece Ended 3 1
Rest of world
Japan, United Kingdom
3

Investigational sites

France

2 sites · Ended
Hospices Civils De Lyon
Centre Hospitalier Lyon Sud Service d’Hématologie Clinique, 165 Chemin Du Grand Revoyet, 69310, Pierre Benite
Centre Hospitalier Universitaire De Lille
Hopital Claude Huriez - Service des maladies du sang, Rue Michel Polonowski, 59000, Lille

Greece

1 site · Ended
Alexandra Hospital
Department of Clinical Therapeutics, Vassilissas Sofias Avenue 80, 115 28, Athens

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
France 2019-10-23 2025-03-17 2019-11-07 2022-03-01
Greece 2022-02-03 2025-02-27 2022-02-08 2022-03-24

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-05-08 France Acceptable
2024-07-05
2024-07-22